Share on

North America CAR T cell Therapy Market Research Report - By Target Antigen, Products, Application, Country (the United States, Canada and Rest of North America) – Industry Analysis on Size, Share, Trends, COVID-19 Impact and Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 9966
Pages: 100
Formats: report pdf report excel report power bi report ppt

North America CAR T cell Therapy Market Size (2022 to 2027)

The size of the CAR T cell Therapy Market in North America is estimated to be valued at USD 1.27 billion by 2027 from USD 0.62 billion in 2022, growing at a remarkable CAGR of 12.88% from 2022 to 2027.

The North America CAR-T cell therapy market is expected to be driven by the rising number of patients presenting a failed response to alternative therapies and the proliferation of cancer across North America. However, the prevalence of cancer cases is expected to increase the demand for a reliable and effective treatment approach to enhance a person's life quality. In addition, other factors such as Favourable reimbursement policies, increasing healthcare spending, and a robust pipeline of medicines are projected to propel the market growth.

Additionally, as the number of adults and children diagnosed with cancer rises, there will be greater demand for an effective and dependable treatment strategy to improve patient quality of life. Therefore, companies are trying to secure the treatment centers to increase patient's access to their treatments. On the other hand, increasing investments and funding by the government and private organizations to develop healthcare and promote research for cell therapy is expected to fuel market growth.

Moreover, identifying novel and effective therapeutic alternatives to treat disease symptoms is a key driver driving the North America CAR-T cell therapy market forward. The FDA has authorized two CAR-T cell treatments, Kymriah and Yescarta, for children with lymphoblastic leukemia and adults with advanced lymphoma, respectively. Over the projected period, this is likely to help the North American CAR T market grow. The major biotech and pharmaceutical companies are implementing various strategies to gain a competitive advantage. The strategies include partnerships, mergers, and acquisitions. 

However, certain factors hamper the North America CAR T market's growth rate. The production of CAR-T cells, for example, is highly complicated, and companies also face logistical issues. Another major challenge is the expense of treatment and reimbursement for this therapy. The cost of therapy is quite costly due to the complicated procedures, and there is no particular package available from healthcare insurance providers for these therapies.

This research report on the North American CAR T Cell therapy market has been segmented and sub-segmented into the following categories.

By Target Antigen:

  • CD20
  • CD19
  • HER2
  • MESO
  • CD22
  • BCMA
  • GD2
  • CD30
  • HER1
  • CD33

By Application:

  • Multiple Myeloma
  • Chronic Lymphocytic Leukemia
  • Mantle Cell Lymphoma
  • Follicular Lymphoma
  • Diffuse large B-cell lymphoma
  • Acute Lymphoblastic Leukemia

By Product: 

  • Allogeneic
  • Autologous

By Therapies: 

  • Axicabtagene ciloleucel (Yescarta)
  • Tisagenlecleucel (Kymriah)

By End User: 

  • Cancer Research Centers
  • Hospitals
  • Academic and Research Institutes
  • Pharmaceutical Companies
  • Biotechnology Companies
  • Contract Research Organizations

By Country: 

  • The United States
  • Canada
  • Rest of North America

Regional Analysis:

Geographically, the North America CAR T market is expected to continue its dominance in the global CAR T Cell therapy market during the forecast period due to the favorable government reimbursement policies and easy and early accessibility of CAR T Cell therapy.

In North America, the U.S. CAR T cell therapy market is expected to lead the North American CAR T Cell therapy market. It is estimated to dominate throughout the forecast period. R&D in the cell therapy area, continuous regular approvals for the products, and the novel drugs associated are causing the market growth in the United States.

The Canadian CAR T cell therapy market is anticipated to have the fastest growth in the forthcoming years, followed by the United States. Escalating expenditure on healthcare, especially in urban areas, is fuelling the market's growth rate. In addition, the rising population and creating awareness through digital advertisements promote the market's growth rate.


A few of the notable companies dominating the North American CAR T cell therapy market profiled in this report are Mustang Bio, Inc., Celgene Corporation, Bluebird Bio, Inc., CARsgen Therapeutics, Ltd., Novartis International AG, Legend Biotech, Sorrento Therapeutics Inc., Kite Pharma, Inc., Immune Therapeutics, Bellicum Pharmaceuticals, Inc. and Pfizer, Inc.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample